SCHEMBL910507

SCHEMBL910507

O=CCCc1cccc(O)c1

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 2/20 0.57
DRD1 P21728 2/20 0.57
TAAR1 Q96RJ0 1/20 0.57
CHRM2 P08172 2/20 0.56
CHRM1 P11229 2/20 0.56
CHRM3 P20309 2/20 0.56
OPRK1 P41145 3/20 0.50
ENPP2 Q13822 1/20 0.50
OPRM1 P35372 2/20 0.49
OPRD1 P41143 2/20 0.49
MGLL Q99685 1/20 0.47
MIF P14174 1/20 0.47
DRD4 P21917 1/20 0.47
DRD5 P21918 1/20 0.47
DRD3 P35462 1/20 0.47
IDO1 P14902 1/20 0.46
HDAC6 Q9UBN7 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30882630 1.00 DRD2 (0.57) DRD2DRD1TAAR1CHRM2CHRM1
SCHEMBL10534002 0.93 OPRK1 (0.54) DRD2DRD1TAAR1CHRM2CHRM1
SCHEMBL9714684 0.89 DRD2 (0.53) DRD2DRD1TAAR1CHRM2CHRM1
SCHEMBL11219508 0.87 MGLL (0.55) DRD2DRD1TAAR1CHRM2CHRM1
SCHEMBL21397284 0.85 MGLL (0.58) DRD2DRD1TAAR1CHRM2CHRM1
SCHEMBL28507389 0.85 MGLL (0.58) DRD2DRD1TAAR1CHRM2CHRM1
SCHEMBL5833923 0.85 MGLL (0.58) DRD2DRD1TAAR1CHRM2CHRM1
SCHEMBL19258592 0.85 MEN1 (0.43) DRD2DRD1TAAR1CHRM2CHRM1
SCHEMBL350297 0.81 ENPP2 (0.56) DRD2DRD1TAAR1CHRM2CHRM1
SCHEMBL723832 0.80 DRD2 (0.74) DRD2DRD1TAAR1CHRM2CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10787484-B2 Compositions and methods for treating cardiovascular disease GENENTECH, INC. (US) 2020-09-29 US claimed
CN-110627832-A Preparation method for synthesizing tenofovir alafenamide by oxidation method 江西农业大学 2019-12-31 CN claimed
US-20190177366-A1 COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE GENENTECH, INC. (US) 2019-06-13 US claimed
CN-104508116-A Pesticidal flavobacterium strains and bioactive compositions, metabolites and uses MARRONE BIO INNOVATIONS INC 2015-04-08 CN claimed
EP-2847318-A1 PESTICIDAL FLAVOBACTERIUM STRAIN AND BIOACTIVE COMPOSITIONS, METABOLITES AND USES Marrone Bio Innovations, Inc. (US) 2015-03-18 EP claimed
US-20150031534-A1 PESTICIDAL FLAVOBACTERIUM STRAIN AND BIOACTIVE COMPOSITIONS METABOLITES AND USES PRO FARM GROUP, INC. 2015-01-29 US claimed
WO-2013138398-A1 PESTICIDAL FLAVOBACTERIUM STRAIN AND BIOACTIVE COMPOSITIONS, METABOLITES AND USES MARRONE BIO INNOVATIONS, INC. (US) 2013-09-19 WO claimed
CN-102936191-A Method for preparing 3-hydroxy phenylpropyl aldehyde from cinnamyl aldehyde UNIV GUANGXI NATIONALITIES 2013-02-20 CN claimed
EP-2210900-A2 Analogues of GLP-1 IPSEN PHARMA (FR) 2010-07-28 EP claimed
US-20090300800-A1 D-Amino Acid a Selectable Marker for Barley (Hordeum Vulgare L.) Transformation BASF PLANT SCIENCE GMBH (DE) 2009-12-03 US claimed
WO-2005058955-A1 ANALOGUES OF GLP-1 SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES S.A.S. (FR) 2005-06-30 WO claimed
EP-0929574-B1 MODULATORS OF beta-AMYLOID PEPTIDE AGGREGATION COMPRISING D-AMINO ACIDS PRAECIS PHARM INC (US) 2005-06-29 EP claimed
US-20020103134-A1 Modulators of beta-amyloid peptide aggregation comprising D-amino acids PRAECIS PHARMACEUTICALS INC. 2002-08-01 US claimed
US-5985242-A PEPTIDE OF 3 TO 5 D-AMINO ACIDS; MAY BE MODIFIED AT AMINO-AND/OR CARBOXY TERMINUS; FOR TREATMENT OF AMYLOIDOSIS, ALZHEIMER'S DISEASE PRAECIS PHARMACEUTICALS, INC. (US) 1999-11-16 US claimed
EP-0929574-A1 MODULATORS OF beta-AMYLOID PEPTIDE AGGREGATION COMPRISING D-AMINO ACIDS Praecis Pharmaceuticals Incorporated (US) 1999-07-21 EP claimed
WO-1998008868-A9 MODULATORS OF β-AMYLOID PEPTIDE AGGREGATION COMPRISING D-AMINO ACIDS 1998-05-28 WO claimed
WO-1998008868-A1 MODULATORS OF β-AMYLOID PEPTIDE AGGREGATION COMPRISING D-AMINO ACIDS PRAECIS PHARMACEUTICALS INCORPORATED (US) 1998-03-05 WO claimed
EP-0297435-B1 AMINOPROPANOL DERIVATIVES OF 3-(3'-HYDROXYPHENYL)-1-PROPANONE, PROCESS FOR THEIR PREPARATION AND MEDICINES CONTAINING THESE COMPOUNDS Helopharm W. Petrik GmbH & Co.KG. (DE) 1991-10-16 EP claimed
EP-0297435-A2 Aminopropanol derivatives of 3-(3'-hydroxyphenyl)-1-propanone, process for their preparation and medicines containing these compounds Helopharm W. Petrik GmbH & Co.KG. (DE) 1989-01-04 EP claimed
EP-0296265-A1 Aminopropanol derivatives of 3-(3-hydroxyphenyl)-1-propanone, process for their preparation and medicines containing these compounds Helopharm W. Petrik GmbH & Co.KG. (DE) 1988-12-28 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020103134-A1 Modulators of beta-amyloid peptide aggregation comprising D-amino acids IAPP, APP, VIP DRD2 517/4885DRD1 533/4885TAAR1 4007/4885
US-20150031534-A1 PESTICIDAL FLAVOBACTERIUM STRAIN AND BIOACTIVE COMPOSITIONS METABOLITES AND USES BLVRB, PRDX6, ACHE DRD2 2889/4885DRD1 3037/4885TAAR1 1632/4885
US-10787484-B2 Compositions and methods for treating cardiovascular disease PCSK9, PCSK7, PCSK6 DRD2 4852/4885DRD1 4870/4885TAAR1 4623/4885
US-20190177366-A1 COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE PCSK9, PCSK7, PCSK6 DRD2 4852/4885DRD1 4870/4885TAAR1 4623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.